RIA Advisory Group LLC Invests $281,000 in Novo Nordisk A/S (NYSE:NVO)

RIA Advisory Group LLC acquired a new stake in Novo Nordisk A/S (NYSE:NVO) during the third quarter, according to its most recent filing with the SEC. The firm acquired 2,360 shares of the company’s stock, valued at approximately $281,000.

A number of other large investors also recently bought and sold shares of the company. 1620 Investment Advisors Inc. acquired a new stake in Novo Nordisk A/S in the second quarter valued at about $25,000. Gilliland Jeter Wealth Management LLC boosted its stake in shares of Novo Nordisk A/S by 200.0% in the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after buying an additional 120 shares in the last quarter. Strategic Investment Solutions Inc. IL acquired a new position in Novo Nordisk A/S during the second quarter worth $25,000. Orion Capital Management LLC purchased a new position in Novo Nordisk A/S in the first quarter worth $26,000. Finally, Halpern Financial Inc. lifted its holdings in Novo Nordisk A/S by 113.0% in the second quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock valued at $30,000 after acquiring an additional 113 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Finally, BMO Capital Markets lowered their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Novo Nordisk A/S has a consensus rating of “Buy” and an average price target of $144.50.

Novo Nordisk A/S Trading Down 3.4 %

Shares of NVO traded down $3.58 on Friday, hitting $101.74. 8,076,248 shares of the stock traded hands, compared to its average volume of 4,457,389. The firm has a market capitalization of $456.56 billion, a P/E ratio of 32.93, a P/E/G ratio of 1.31 and a beta of 0.42. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 1 year low of $94.73 and a 1 year high of $148.15. The stock’s 50 day moving average is $118.58 and its two-hundred day moving average is $129.58.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.